CoronaryAtlas logo
CoronaryAtlas
ESR1
Pathway / Off-pathway / systemic markers

ESR1

ESR1gene

ESR1 hypermethylation associates with coronary heart disease and may alter estrogen-mediated vascular homeostasis and inflammation.

Pathway placement
Cascade stepOff-pathway / systemic markers
Confidencelow
RationaleHypermethylation in CHD; estrogen signaling modulates vascular inflammation.
Also acts inVascular inflammation
Druggability
Not assessed (no mapped human gene target).

Type I vs non-Type I discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
41
C — non-Type-I
64
A — assay feasibility
52
E — evidence strength
26
T1DI (composite)
5
Specificity differential (R−C)-22.8
Non-Type-I axis panel
Does this marker also move in each non-Type-I setting? mag 0–3; higher means less Type-I-specific. n/a = no evidence retrieved, which is not the same as no change.
No non-Type-I axis evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Whole blood — gene is not a circulating analyte; measure protein product or genotype
Collection tube
K2-EDTA whole blood (lavender-top)
Method / principle
SNP genotyping / sequencing; or immunoassay of encoded protein
Reagent / substrate
Allele-specific primers/probes (TaqMan) or NGS panel; or antibody for protein
Platform
qPCR / NGS / array
Turnaround · availability
Send-out · Genotyping widely available; protein assay variable

Literature evidence(1)